{
  "symbol": "MGNX",
  "company_name": "Macrogenics",
  "ir_website": "https://ir.macrogenics.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "MacroGenics to Participate in Upcoming Investor Conference",
          "url": "https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-participate-upcoming-investor-conference-5",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# Press Release\n\n<< [Back](#)\n\nDec 2, 2024\n\nMacroGenics to Participate in Upcoming Investor Conference\n\nROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:\n\n  * **7th Annual Evercore HealthCONx ( Coral Gables, FL).** MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30am ET. MacroGenics’ management will also participate in one-on-one meetings.\n\n\n\nA webcast of the above presentation may be accessed under \"Events & Presentations\" in the Investor Relations section of MacroGenics' website at [http://ir.macrogenics.com/events.cfm](https://www.globenewswire.com/Tracker?data=dWn9PmATqj8cHSaIClTgRoodoMY25cwVyztYRoftxdB3-dlOT3Y-TlXV2fJ1zgDAxILBDTB8WX1e5IMVvx4ak6nlxa_VdMCqvCRX9ai_0w037Fi-punPVGxx_HLAFgMIm_UhJzF9z9_jTnFp0AmPx9tVCWSEDgQw_vD1fzS9o6m5vQlgIDXz6AkFnDatUMQ8tMqOVuhR31YU0BMwK6xgmLGMn3QdYC56Y1N-rJrHfFPODrTkcf2oIH-hj0prGDdQYZ7ilHV6nmJfcPTURUd5cnTBGiBsvZIUpMMIOMCue5uWwfis43lDiGbvK801et4BAxKCLeU4C7O6sKEWkT5hSt1SpCqrth8wBJIOrv_xUHMxT_Xu8lz60i1LOQWnhFfnK8WwHuLuNUu-MVJAhRH1R_1UuQL7y3cKLOBt-2zxQPjilv8uoF6PYyPYTl8h-HeMJw_4X3GXkeEDk4o9ghYUSwUYqKWBlWJdlsTWW8-KJNojfAmZir2LdUUleb3WhEO8-B_nntIWx3OO87GxPjRdfvdCsD5PtEkYW5egmmqzp1R9RrIBW9mC7gSGOClm6G3aO4gw5TrXRfMbozPtV0jEFvUIND4rMeAp508fLrLhiwo7atunOjv2UTdQ78_Lh1pglhFCAiXUZ773iCLMgM0anw==). The Company will maintain an archived replay of this webcast on its website for 30 days.\n\n**About MacroGenics, Inc.**\n\nMacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at [www.macrogenics.com](https://www.globenewswire.com/Tracker?data=G3gFd4MiUNkf4eVnKz8KjSQURHNelDfNlq5YDbaDxZh9SHwdp8Tiyi7CuG8rHPoBHr_3MJHLJkBNVP7dzGkep9hGfLUAIWI0cQ5ILPVy-XRs2KLNUwJUBgxrgvu0vYQEz-QCbcGuVB3b-weu3AKyDN0862Q7odijv_DDLdgR0v7CsoaUGkDNvsXnf81QuONedlQE4-Hr7i8UIw2L9M4LEsJoaJmjcQnLTaPiLas2ZfTTt5RQEJsyE7D45R1JqrAhv5jbEQdwmbN3Z6tmHJh7nUUFL_tIqqCZgjXKs6ZgkjDaHhKpJ8jSUL19-QhgL13_UIgfEWegDYm5pD5mlZsyVaCjPBJ57nIf4HgPCrm3J2ZnFEbrObldMgJez5qa0nkKSb658hq1BjXxrEqhvf9qfHs1D7teBu30FNox8L_MohBqRhTSRF1c6r-650XNcUN_Pff42UwkahH34HmQHdk81bsdIgyeyEWgXqq7gGDtaQZ9T6V5dkC4Gp2NYVxymdOLaCotb3_SIj841sVnhNbcBtKgVjVbu7EO_f7APB6MCl29mj-IITPfeYX_unqtgzfhHaFFCoGhgA9hbye7yIBl4JVOQHyxfxXryPcGJd07ZDtdlHwYFVBNXa9_FgoNa7JU). MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.\n\n###\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTMxMjc1OCM2NjE5MDM3IzIwMDg5NTc=)![](https://ml.globenewswire.com/media/MTA4MjU4YjYtYzZhNy00ZDVmLWFkM2UtNzYwZWNmZmViOWYwLTEwMjA1MzA=/tiny/MacroGenics-Inc-.png)```\nCONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172,  info@macrogenics.com\n```\n\n[![Primary Logo](https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/72a7b58c-b7ca-4cd5-b2bb-185124351f1c)\n\nSource: MacroGenics, Inc.\n"
        },
        {
          "title": "MacroGenics to Participate in Upcoming Investor Conferences",
          "url": "https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-participate-upcoming-investor-conferences-26",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# Press Release\n\n<< [Back](#)\n\nNov 6, 2024\n\nMacroGenics to Participate in Upcoming Investor Conferences\n\nROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:\n\n  * **Guggenheim Securities Healthcare Innovation Conference (Boston).** MacroGenics’ Chief Operating Officer, Eric Risser, will participate in a fireside chat on Tuesday, November 12, 2024, at 4:00pm ET. MacroGenics’ management will also participate in one-on-one meetings. \n  * **Stifel 2024 Healthcare Conference ( New York). **MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Monday, November 18, 2024, at 1:15pm ET. MacroGenics’ management will also participate in one-on-one meetings.\n\n\n\nWebcasts of the above presentations may be accessed under \"Events & Presentations\" in the Investor Relations section of MacroGenics' website at <http://ir.macrogenics.com/events.cfm>. The Company will maintain archived replays of these webcasts on its website for 30 days.\n\n**About MacroGenics, Inc.**\n\nMacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at [www.macrogenics.com](http://www.macrogenics.com). MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.\n\n###\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2ODgzMSM2NTY5NDkxIzIwMDg5NTc=)![](https://ml.globenewswire.com/media/ZjE4ZTY4NjgtZmEyYy00MzYyLWI4NTAtZjYxNDljMGFiNTlhLTEwMjA1MzA=/tiny/MacroGenics-Inc-.png)```\nCONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com\n```\n\n[![Primary Logo](https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/72a7b58c-b7ca-4cd5-b2bb-185124351f1c)\n\nSource: MacroGenics, Inc.\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "7th Annual Evercore HealthCONx (Coral Gables, FL)",
          "url": "https://ir.macrogenics.com/events/event-details/7th-annual-evercore-healthconx-coral-gables-fl",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# Event Details\n\n## 7th Annual Evercore HealthCONx (Coral Gables, FL)\n\n###  Dec 4, 2024 7:30 AM EST\n\n[Add to Outlook](/node/15521/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=MacroGenics, Inc. - 7th Annual Evercore HealthCONx \\(Coral Gables, FL\\)&dates=20241204T123000Z/20241204T123000Z&details=Event Details: http://ir.macrogenics.com/events/event-details/7th-annual-evercore-healthconx-coral-gables-fl%0A%0AWebcast: https://wsw.com/webcast/evercore44/mgnx/2386062&location=&trp=false&sprop=&sprop=name:)\n\n[Listen to webcast](https://wsw.com/webcast/evercore44/mgnx/2386062)\n"
        },
        {
          "title": "Stifel 2024 Healthcare Conference (New York)",
          "url": "https://ir.macrogenics.com/events/event-details/stifel-2024-healthcare-conference-new-york",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# Event Details\n\n## Stifel 2024 Healthcare Conference (New York)\n\n###  Nov 18, 2024 1:15 PM EST\n\n[Listen to webcast](https://wsw.com/webcast/stifel96/mgnx/2118332)\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.macrogenics.com/financial-information/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# SEC Filings\n\n#  SEC Filings \n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -2024202320222021202020192018201720162015201420132012201120102009200820072006200520042003\n\n- Any -\n\nItems per page 102550\n\n10\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | View  \n---|---|---|---  \nNov 21, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001125345-24-000165) | Report of unscheduled material events or corporate event | [View HTML](/node/15516/html) [0001125345-24-000165.pdf](/static-files/2cfa0e4c-157d-45c3-bdfa-e845bca5f4c5) [0001125345-24-000165.xls](/static-files/7718c584-cb13-44ec-afcf-1ecde747435c) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001125345-24-000165)  \nNov 20, 2024 | [SC 13G](/sec-filings/sec-filing/sc-13g/0001193125-24-262283) | A statement of beneficial ownership of common stock by certain persons | [View HTML](/node/15511/html) [0001193125-24-262283.pdf](/static-files/a24cd9dc-33e0-4c47-b9a8-c85f01ab1c86) [0001193125-24-262283.xls](/static-files/f99a1749-b820-4f0a-87aa-aaad3ce932c8)  \nNov 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001172661-24-005318) | An amendment to the SC 13G filing | [View HTML](/node/15506/html) [0001172661-24-005318.pdf](/static-files/fbc5060e-8fec-45d0-88f0-401a32c3012b) [0001172661-24-005318.xls](/static-files/96559c31-ea3e-4c4e-a459-e4ea4bbc70ce)  \nNov 8, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0002012383-24-003643) | An amendment to the SC 13G filing | [View HTML](/node/15501/html) [0002012383-24-003643.pdf](/static-files/e3c928bc-4cc9-4293-ba31-8609da9be0b9)  \nNov 5, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001125345-24-000160) | Quarterly report which provides a continuing view of a company's financial position | [View HTML](/node/15481/html) [0001125345-24-000160.pdf](/static-files/e3dd21ae-50a9-4242-858d-31bd8bb3652d) [0001125345-24-000160.xls](/static-files/8914bea5-1ad2-4a28-a02f-a045b58df18f) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001125345-24-000160)  \nNov 5, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001125345-24-000161) | Report of unscheduled material events or corporate event | [View HTML](/node/15486/html) [0001125345-24-000161.pdf](/static-files/5ba00411-95b4-41b8-a71f-d733f4a4cba9) [0001125345-24-000161.xls](/static-files/68c48b12-2b40-4fc0-86d8-59f16b8ec21a) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001125345-24-000161)  \nOct 30, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001193125-24-247017) | Report of unscheduled material events or corporate event | [View HTML](/node/15461/html) [0001193125-24-247017.pdf](/static-files/bb5c8608-617c-4cfc-90c7-e4a0d5ded629) [0001193125-24-247017.xls](/static-files/a6d8790f-367f-420a-aabb-1211785d7661) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193125-24-247017)  \nOct 22, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0002012383-24-001300) | An amendment to the SC 13G filing | [View HTML](/node/15436/html) [0002012383-24-001300.pdf](/static-files/1182ae11-86ca-42f5-8489-6a1128a6db3e)  \nOct 9, 2024 | [4](/sec-filings/sec-filing/4/0001125345-24-000155) | Statement of changes in beneficial ownership of securities | [View HTML](/node/15426/html) [0001125345-24-000155.pdf](/static-files/75d3342f-2a23-41cc-bde3-ae1437d2aab2) [0001125345-24-000155.xls](/static-files/a836040e-c927-4efd-ac0d-d7969d385538)  \nSep 25, 2024 | [4](/sec-filings/sec-filing/4/0001125345-24-000153) | Statement of changes in beneficial ownership of securities | [View HTML](/node/15416/html) [0001125345-24-000153.pdf](/static-files/075da6ed-f68c-4bf1-9adf-6228a8f9c187) [0001125345-24-000153.xls](/static-files/a3d0988e-e4e9-492f-90b2-9ecbfe11d484)\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://ir.macrogenics.com/financial-information/quarterly-results",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# Quarterly Results\n\n#  Quarterly Results \n\n[Show all](#)\n\n## 2024\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-third-quarter)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-24-000160)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-second-quarter)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-24-000148)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-first-quarter)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-24-000088)\n\n\n\n\n## 2023\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2023 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2023)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001125345-24-000060)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-6)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-23-000124)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-7)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-23-000108)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-6)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-23-000076)\n\n\n\n\n## 2022\n\nQ4\n\n  * [MacroGenics Provides Corporate Update and 2022 Financial Results](/news-releases/news-release-details/macrogenics-provides-corporate-update-and-2022-financial-results)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001125345-23-000059)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results](/news-releases/news-release-details/macrogenics-provides-corporate-update-and-third-quarter-2022)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-22-000104)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-6)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-22-000090)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-5)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-22-000047)\n\n\n\n\n## 2021\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2021 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2021)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001125345-22-000013)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-5)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-21-000115)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-5)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-21-000099)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-4)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001125345-21-000060)\n\n\n\n\n## 2020\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2020 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2020)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001125345-21-000035)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-4)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-4)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-3)\n\n\n\n\n## 2019\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2019 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2019)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-3)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-3)\n\n\n\n\nQ1\n\n  * [MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call](/news-releases/news-release-details/macrogenics-announces-date-first-quarter-2019-financial-results)\n\n\n\n\n## 2018\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2018 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2018)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-3rd-quarter)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2nd-quarter)\n\n\n\n\nQ1\n\n  * [MacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call](/news-releases/news-release-details/macrogenics-announces-date-first-quarter-2018-financial-results)\n\n\n\n\n## 2017\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2017 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2017)\n\n\n\n\nQ3\n\n  * [MacroGenics, Inc. Third Quarter 2017 Financial Results Conference Call](/events/event-details/macrogenics-inc-third-quarter-2017-financial-results-conference-call)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-2)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-1st-quarter)\n\n\n\n\n## 2016\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2016 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2016)\n\n\n\n\nQ3\n\n  * [MacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-1)\n\n\n\n\nQ2\n\n  * [MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-1)\n\n\n\n\nQ1\n\n  * [MacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-1)\n\n\n\n\n## 2015\n\nQ4\n\n  * [MacroGenics Provides Update on Corporate Progress and 2015 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2015)\n\n\n\n\nQ3\n\n  * [Third Quarter 2015 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-0)\n\n\n\n\nQ2\n\n  * [Second Quarter 2015 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-0)\n\n\n\n\nQ1\n\n  * [First Quarter 2015 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-0)\n\n\n\n\n## 2014\n\nQ4\n\n  * [Fourth Quarter 2014 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2014)\n\n\n\n\nQ3\n\n  * [Third Quarter 2014 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-third-quarter)\n\n\n\n\nQ2\n\n  * [Second Quarter 2014 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second)\n\n\n\n\nQ1\n\n  * [First Quarter 2014 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-first-quarter)\n\n\n\n\n## 2013\n\nQ4\n\n  * [Fourth Quarter 2013 Financial Results](/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-2013)\n\n\n\n\nQ3\n\n  * [Third Quarter 2013 Financial Results](/news-releases/news-release-details/macrogenics-provides-corporate-progress-update-and-third-quarter)\n\n\n\n"
        },
        {
          "title": "Key Metrics",
          "url": "https://ir.macrogenics.com/financial-information/key-ratios",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[![](/sites/g/files/knoqqb20736/themes/site/nir_pid1875/client/images/MacroGenics-logo.png)](http://www.macrogenics.com/)\n\n# Key Metrics\n\n#  Key Metrics \n\n## Price & Volume\n\nRecent Price  | $3.69  \n---|---  \nRecent Price  | 12/2/24  \n52 Week High  | $21.88  \n52 Week Low  | $2.95  \n5 Day Price Percent Change (%)  | 13.89%  \n4 Week Price Percent Change (%)  | -0.27%  \n26 Week Price Percent Change (%)  | -17.63%  \n52 Week Price Percent Change (%)  | -55.97%  \nVolume (3 Month Average) (Mil)  | 13.52  \nVolume (10 Day Average) (Mil)  | 0.48  \nBeta  | 2.02  \n  \n## Share Related Items\n\nMarket Capitalization (Mil)  | $231.60  \n---|---  \nShares Outstanding (Mil)  | 62.76  \nShares Outstanding, Average (FY) (Mil)  | 61.93  \nFloat (Mil)  | 61.11  \n  \n## Dividend Information\n\nYield (%)  | --  \n---|---  \nEx-Dividend Date   \nDividend Rate  | --  \n  \n## Financial Strength\n\nQuick Ratio (MRQ)  | 3.69  \n---|---  \nQuick Ratio (FY))  | 4.46  \nCurrent Ratio (MRQ)  | 3.75  \nCurrent Ratio (FY)  | 4.48  \nLT Debt to Equity (MRQ) (%)  | --  \nLT Debt to Equity (FY) (%)  | --  \nTotal Debt to Equity (MRQ) (%)  | --  \nTotal Debt to Equity (FY) (%)  | --  \n  \n## Valuation Ratios\n\nP/E (TTM)  | --  \n---|---  \nP/E (FY)  | --  \nP/E 5 Fiscal Year High  | --  \nP/E 5 Fiscal Year Low  | --  \nPrice to Revenue (TTM)  | 1.64  \nPrice to Revenue (MRQ)  | 0.52  \nPrice to Revenue (FY)  | 3.94  \nPrice to Cash Flow (TTM)  | --  \nPrice to Cash Flow (MRQ)  | 0.99  \nPrice to Cash Flow (FY)  | 395.22  \nPrice to Free Cash Flow (TTM)  | --  \nPrice to Free Cash Flow (FY)  | --  \nPrice to Book (MRQ)  | 1.93  \nPrice to Book (FY)  | 1.50  \nPrice to Tangible Book (MRQ)  | 1.93  \nPrice to Tangible Book (FY)  | 1.52  \nPrice to Tangible Book - Common (MRQ)  | 1.72  \nPrice to Tangible Book - Common (FY)  | 3.91  \n  \n## Per Share Data\n\nRevenue/Share (TTM)  | $2.26  \n---|---  \nRevenue/Share (MRQ)  | $7.06  \nRevenue/Share (FY)  | $0.95  \nEPS Fully Diluted (TTM)  | $-1.57  \nEPS Fully Diluted (MRQ)  | $0.90  \nBook Value/Share (MRQ)  | $1.91  \nBook Value/Share (FY)  | $2.46  \nCash Flow/Share (TTM)  | $-1.44  \nCash Flow/Share (MRQ)  | $3.71  \nCash Flow/Share (FY)  | $0.01  \nCash (MRQ)  | $3.19  \nCash (FY)  | $3.70  \n  \n## Mgmt Effectiveness\n\nReturn on Equity (TTM) (%)  | -62.17  \n---|---  \nReturn on Equity (MRQ) (%)  | 253.93  \nReturn on Equity (FY) (%)  | -6.15  \nReturn on Assets (TTM) (%)  | -32.30  \nReturn on Assets (MRQ) (%)  | 97.01  \nReturn on Assets (FY) (%)  | -3.13  \nReturn on Investment (TTM) (%)  | -39.53  \nReturn on Investment (MRQ) (%)  | 129.65  \nReturn on Investment (FY) (%)  | -3.82  \n  \n## Profitability\n\nOperating Margin (TTM) (%)  | -75.78  \n---|---  \nOperating Margin (MRQ) (%)  | 48.95  \nOperating Margin (FY) (%)  | -29.47  \nNet Profit Margin (TTM) (%)  | -69.07  \nNet Profit Margin (MRQ) (%)  | 50.86  \nNet Profit Margin (FY) (%)  | -15.42  \nGross Margin (TTM) (%)  | 95.07  \nGross Margin (MRQ) (%)  | 98.31  \nGross Margin (FY) (%)  | 86.00  \n  \nFY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.\n\nSource: LSEG\n"
        }
      ]
    }
  ]
}